Oppenheimer raised the firm’s price target on Voyager Therapeutics (VYGR) to $18 from $16 and keeps an Outperform rating on the shares. Voyager Therapeutics started 2024 by announcing another notable deal with Novartis (NVS). The expanded collaboration advances potential gene therapies for Huntington’s disease and spinal muscular atrophy. The firm views the expanded collaboration with Novartis as adding further external validation to Voyager’s platform, with additional thoughts on recent news and read-across below.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on VYGR:
- Voyager Therapeutics price target raised to $18 from $15 at Baird
- Wells Fargo upgrades Voyager on ‘highly validating’ Novartis deal
- Wells Fargo upgrades Novartis on ‘highly validating’ Novartis deal
- Voyager Therapeutics upgraded to Overweight from Equal Weight at Wells Fargo
- Voyager (NASDAQ:VYGR) Skyrockets on ~$1.3B Licensing Deal with Novartis
